Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Leukemia

Free Subscription 11.02.2019 1 Am J Hematol 1 Biochem Biophys Res Commun 4 Blood 2 Bone Marrow Transplant 11 Br J Haematol 1 Cancer 1 Cancer Chemother Pharmacol 1 Cancer Res 1 Cell 1 Genes Chromosomes Cancer 2 Int J Hematol 2 J Immunol 1 J Pediatr Hematol Oncol 12 Leuk Lymphoma 1 Leuk Res 4 Leukemia 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Hematol

1. SUI JN, Chen QS, Zhang YX, Sheng Y, et al
   Identifying Leukemia-Associated Immunophenotype-based Individualized Minimal Residual Disease in Acute Myeloid Leukemia and its Prognostic Significance.
   Am J Hematol. 2019 Feb 7. doi: 10.1002/ajh.25431.
   PubMed     Text format     Abstract available
   
   

   
   Biochem Biophys Res Commun

2. FERNANDES MT, Caroco LS, Pacheco-Leyva I, Dos Santos NR, et al
   NF-kappaB-dependent RANKL expression in a mouse model of immature T-cell leukemia.
   Biochem Biophys Res Commun. 2019 Jan 30. pii: S0006-291X(19)30115.
   PubMed     Text format     Abstract available
   
   

   
   Blood

3. HETZNER K, Garcia-Cuellar MP, Buttner C, Slany RK, et al
   The interaction of ENL with PAF1 mitigates polycomb silencing and facilitates murine leukemogenesis.
   Blood. 2018;131:662-673.
   PubMed     Text format     Abstract available
   
   
4. VOISSET E, Moravcsik E, Stratford EW, Jaye A, et al
   Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.
   Blood. 2018;131:636-648.
   PubMed     Text format     Abstract available
   
   
5. LAZAREVIC V, Orsmark-Pietras C, Lilljebjorn H, Pettersson L, et al
   Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow.
   Blood. 2018;131:577-581.
   PubMed     Text format    
   
   
6. GREEN DJ, O'Steen S, Lin Y, Comstock ML, et al
   CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
   Blood. 2018;131:611-620.
   PubMed     Text format     Abstract available
   
   

   
   Bone Marrow Transplant

7. BATTIPAGLIA G, Boumendil A, Labopin M, Ciceri F, et al
   Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT.
   Bone Marrow Transplant. 2019 Feb 4. pii: 10.1038/s41409-019-0459.
   PubMed     Text format     Abstract available
   
   
8. OKAMOTO Y, Kudo K, Tabuchi K, Tomizawa D, et al
   Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia.
   Bone Marrow Transplant. 2019 Feb 4. pii: 10.1038/s41409-019-0461.
   PubMed     Text format     Abstract available
   
   

   
   Br J Haematol

9. GUZELKUCUK Z, Isik M, Ozcan AS, Demirkan TH, et al
   Imatinib-related interstitial lung disease.
   Br J Haematol. 2018;180:780.
   PubMed     Text format    
   
   
10. JURCZYSZYN A, Radocha J, Davila J, Fiala MA, et al
    Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.
    Br J Haematol. 2018;180:831-839.
    PubMed     Text format     Abstract available
    
    
11. SHRUBSOLE C, Collin M
    Tumour genesis syndrome in relapsed B lymphoblastic leukaemia.
    Br J Haematol. 2018;181:160.
    PubMed     Text format    
    
    
12. RASHIDI A, Weisdorf DJ, Bejanyan N
    Treatment of relapsed/refractory acute myeloid leukaemia in adults.
    Br J Haematol. 2018;181:27-37.
    PubMed     Text format     Abstract available
    
    
13. HOBO W, Hutten TJA, Schaap NPM, Dolstra H, et al
    Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword.
    Br J Haematol. 2018;181:38-53.
    PubMed     Text format     Abstract available
    
    
14. KONG Y, Song Y, Tang FF, Zhao HY, et al
    N-acetyl-L-cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-allotransplant.
    Br J Haematol. 2018;180:863-878.
    PubMed     Text format     Abstract available
    
    
15. GUTIERREZ A, Kentsis A
    Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy.
    Br J Haematol. 2018;180:919-924.
    PubMed     Text format     Abstract available
    
    
16. STECKEL NK, Groth C, Mikesch JH, Trenschel R, et al
    High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia.
    Br J Haematol. 2018;180:840-853.
    PubMed     Text format     Abstract available
    
    
17. CRASSINI KR, Zhang E, Balendran S, Freeman JA, et al
    Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia.
    Br J Haematol. 2018;181:97-101.
    PubMed     Text format     Abstract available
    
    
18. OSTGARD LSG, Norgaard M, Pedersen L, Ostgard RD, et al
    Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study.
    Br J Haematol. 2018;181:205-214.
    PubMed     Text format     Abstract available
    
    
19. RIGOLIN GM, Saccenti E, Guardalben E, Cavallari M, et al
    In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.
    Br J Haematol. 2018;181:229-233.
    PubMed     Text format     Abstract available
    
    

    
    Cancer

20. D'ADDA M, Farina M, Schieppati F, Borlenghi E, et al
    The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31977.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Chemother Pharmacol

21. NIKANJAM M, Capparelli EV, Lancet JE, Louie A, et al
    Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
    Cancer Chemother Pharmacol. 2018;81:171-178.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

22. JIA B, Zhao C, Rakszawski KL, Claxton DF, et al
    Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia (AML).
    Cancer Res. 2019 Feb 1. pii: 0008-5472.CAN-18-3107.
    PubMed     Text format     Abstract available
    
    

    
    Cell

23. XIAO G, Chan LN, Klemm L, Braas D, et al
    B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.
    Cell. 2018;173:470-484.
    PubMed     Text format     Abstract available
    
    

    
    Genes Chromosomes Cancer

24. PAULRAJ P, Diamond S, Razzaqi F, Ozeran D, et al
    Pediatric acute myeloid leukemia with t(7;21)(p22;q22).
    Genes Chromosomes Cancer. 2019 Jan 31. doi: 10.1002/gcc.22740.
    PubMed     Text format     Abstract available
    
    

    
    Int J Hematol

25. HATSUMI N, Miyawaki S, Yamauchi T, Takeshita A, et al
    Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
    Int J Hematol. 2019 Feb 6. pii: 10.1007/s12185-019-02606.
    PubMed     Text format     Abstract available
    
    
26. YAMASHITA Y, Nishikawa A, Iwahashi Y, Fujimoto M, et al
    Identification of a novel CCDC22 mutation in a patient with severe Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and aggressive natural killer cell leukemia.
    Int J Hematol. 2019 Jan 31. pii: 10.1007/s12185-019-02595.
    PubMed     Text format     Abstract available
    
    

    
    J Immunol

27. ARRUDA LCM, Gaballa A, Uhlin M
    Graft gammadelta TCR Sequencing Identifies Public Clonotypes Associated with Hematopoietic Stem Cell Transplantation Efficacy in Acute Myeloid Leukemia Patients and Unravels Cytomegalovirus Impact on Repertoire Distribution.
    J Immunol. 2019 Feb 1. pii: jimmunol.1801448. doi: 10.4049/jimmunol.1801448.
    PubMed     Text format     Abstract available
    
    
28. KAUR M, Drake AC, Hu G, Rudnick S, et al
    Induction and Therapeutic Targeting of Human NPM1c(+) Myeloid Leukemia in the Presence of Autologous Immune System in Mice.
    J Immunol. 2019 Feb 1. pii: jimmunol.1800366. doi: 10.4049/jimmunol.1800366.
    PubMed     Text format     Abstract available
    
    

    
    J Pediatr Hematol Oncol

29. CELKAN T, Kizilocak H, Evim M, Meral Gunes A, et al
    Hepatosplenic Fungal Infections in Children With Leukemia-Risk Factors and Outcome: A Multicentric Study.
    J Pediatr Hematol Oncol. 2019 Feb 5. doi: 10.1097/MPH.0000000000001431.
    PubMed     Text format     Abstract available
    
    

    
    Leuk Lymphoma

30. WALZ JS, Kowalewski DJ, Backert L, Nelde A, et al
    Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers.
    Leuk Lymphoma. 2018;59:1949-1958.
    PubMed     Text format     Abstract available
    
    
31. MA J, Dunlap J, Paliga A, Traer E, et al
    DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.
    Leuk Lymphoma. 2018;59:1938-1948.
    PubMed     Text format     Abstract available
    
    
32. SASAKI K, Mori Y, Yoshimoto G, Sakoda T, et al
    Successful treatment of Ph ALL with hematopoietic stem cell transplantation from the same HLA-haploidentical related donor of previous liver transplantation.
    Leuk Lymphoma. 2017 Nov 22:1-3. doi: 10.1080/10428194.2017.1403021.
    PubMed     Text format    
    
    
33. SHEN Y, Best OG, Mulligan SP, Christopherson RI, et al
    Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.
    Leuk Lymphoma. 2018;59:1927-1937.
    PubMed     Text format     Abstract available
    
    
34. AW A, Kim HT, Fernandes SM, Hoang K, et al
    Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry.
    Leuk Lymphoma. 2018;59:1986-1989.
    PubMed     Text format    
    
    
35. ESKAZAN AE
    Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?
    Leuk Lymphoma. 2019 Feb 4:1-2. doi: 10.1080/10428194.2019.1571202.
    PubMed     Text format    
    
    
36. NATARAJAN H
    Plasma imatinib trough level measurements is still appropriate to predict therapeutic responses in patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Feb 4:1-2. doi: 10.1080/10428194.2019.1571206.
    PubMed     Text format    
    
    
37. ZHANG J, Yang F, Qiu HY, Wu Q, et al
    Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Leuk Lymphoma. 2019 Feb 4:1-8. doi: 10.1080/10428194.2018.1533127.
    PubMed     Text format     Abstract available
    
    
38. XU Y, Zhou X, Li Y, Zhang Y, et al
    Suppression of minichromosome maintenance 7 expression sensitizes chronic lymphocytic leukemia cells to fludarabine.
    Leuk Lymphoma. 2019 Feb 4:1-9. doi: 10.1080/10428194.2018.1523400.
    PubMed     Text format     Abstract available
    
    
39. BOSE P, Chen LS, Gandhi V
    Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'.
    Leuk Lymphoma. 2019 Feb 6:1-3. doi: 10.1080/10428194.2019.1571207.
    PubMed     Text format    
    
    
40. WINESTONE LE, Getz KD, Rao P, Li Y, et al
    Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment.
    Leuk Lymphoma. 2019 Feb 7:1-9. doi: 10.1080/10428194.2019.1574002.
    PubMed     Text format     Abstract available
    
    
41. DAI K, Zhang Q, Li Y, Wu L, et al
    Plasma fibrinogen levels correlate with prognosis and treatment outcome in patients with non-M3 acute myeloid leukemia.
    Leuk Lymphoma. 2019 Feb 8:1-9. doi: 10.1080/10428194.2018.1535116.
    PubMed     Text format     Abstract available
    
    

    
    Leuk Res

42. BELL JA, Galaznik A, Farrelly E, Blazer M, et al
    A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.
    Leuk Res. 2019;78:45-51.
    PubMed     Text format     Abstract available
    
    

    
    Leukemia

43. GUENOT C, Lacombe F, Allou K, Dumezy F, et al
    Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia.
    Leukemia. 2019 Feb 5. pii: 10.1038/s41375-019-0393.
    PubMed     Text format    
    
    
44. GERBOTH S, Frittoli E, Palamidessi A, Baltanas FC, et al
    Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
    Leukemia. 2018;32:820-827.
    PubMed     Text format     Abstract available
    
    
45. ANDERSSON EI, Putzer S, Yadav B, Dufva O, et al
    Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
    Leukemia. 2018;32:774-787.
    PubMed     Text format     Abstract available
    
    
46. BENARD B, Gentles AJ, Kohnke T, Majeti R, et al
    Data mining for mutation-specific targets in acute myeloid leukemia.
    Leukemia. 2019 Feb 6. pii: 10.1038/s41375-019-0387.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

47. POULARD C, Kim HN, Fang M, Kruth K, et al
    Relapse-associated AURKB blunts the glucocorticoid sensitivity of B cell acute lymphoblastic leukemia.
    Proc Natl Acad Sci U S A. 2019 Feb 7. pii: 1816254116.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: